PARP1 and breast carcinoma: For example, loss of 53BP1 or components of the non‐homologous end‐joining pathway can suppress the synthetic lethal interaction between poly (ADP‐ribose) polymerase 1 (PARP1) and the breast cancer susceptibility gene BRCA1 [44].